Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients With Advanced Solid Tumor Malignancies or Lymphoma

NCT00322608 is registered in ClinicalTrials.gov with Nereus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00322608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00322608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Vascular Disrupting Agent NPI-2358 Administered Via Intravenous Infusion in Patients With Advanced Solid Tumor Malignancies or Lymphoma
Lead sponsor
Nereus Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2006
Completion date
December 31, 2009
Enrollment
35 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer